PRESS RELEASE published on 11/25/2025 at 18:33, 3 months 28 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 3 months 28 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 4 months 12 days ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
BRIEF published on 11/12/2025 at 07:05, 4 months 12 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
PRESS RELEASE published on 11/12/2025 at 07:00, 4 months 12 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 5 months 2 days ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 5 months 2 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 5 months 2 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce une validation historique dans la revue NATURE confirmant la causalité génétique de l'apolipoprotéine A-I (ApoA-I) dans le sepsis. Une avancée majeure dans le traitement de la septicémie Validation Historique ABIONYX Pharma Nature Septicémie Causalité Génétique
PRESS RELEASE published on 10/21/2025 at 18:49, 5 months 2 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 5 months 17 days ago Franchissement de seuil par la Caisse des dépôts et consignations dans ABIONYX PHARMA Droits De Vote Franchissement De Seuil CDC Bpifrance ABIONYX
Published on 03/24/2026 at 12:35, 14 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 16 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 19 minutes ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 12:30, 19 minutes ago Sidney Resources Corporation Identifies District-Scale Structural and Hydrothermal System at Warren Project; Survey Confirms Strategic Claim Position Within Core Target Corridor
Published on 03/24/2026 at 12:30, 19 minutes ago Avidian Gold Announces Non-Brokered Private Placement for Gross Proceeds of up to $750,000
Published on 03/24/2026 at 12:37, 11 minutes ago CENIT concludes fiscal year 2025 with a strong operational Q4 and looks confidently toward the current year (EBITDA Forecast 2026 +46.6%)
Published on 03/24/2026 at 12:25, 24 minutes ago Athena Intelligence Launches India Push Amid Rising Cross-Border Corporate Risk
Published on 03/24/2026 at 12:23, 25 minutes ago TURKCIMENTO calls for EU-aligned MRV data recognition under CBAM
Published on 03/24/2026 at 11:59, 50 minutes ago Vienna Soil Dialogue: AGRANA shifts focus to soil as a strategic resource key to Europe’s future
Published on 03/24/2026 at 10:58, 1 hour 51 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
Published on 03/24/2026 at 10:58, 1 hour 51 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 28 février 2026
Published on 03/24/2026 at 07:45, 5 hours 4 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 5 hours 4 minutes ago La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 5 hours 19 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
